Latest news and press releases about Atea Pharmaceuticals, Inc. (AVIR): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV).
Price
| Price | $5.15 |
| Market Cap | $412M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 1.84 |
| EV / EBITDA | -2.04 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -64.25% |
| Return on Invested Capital | -86.35% |
| Return on Assets | -71.16% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ACHV · ALLO · ARCT · ENTA · HUMA · PYXS · TRDA
Explore sector: Healthcare · Biotechnology
More sections of AVIR: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks